INTRODUCTION
Tissue regeneration in the intestine is ultimately sustained by intestinal stem cells (ISCs) that reside at the base of mucosal invaginations called crypts ( Figure 1A ). The progeny of ISCs, termed transient amplifying (TA) cells, is expanded through several rounds of mitosis while it migrates upwards along the crypt axis. Close to the intestinal lumen, TA cells undergo cellcycle arrest and terminal differentiation. Stem cells of the mouse small intestine (Barker et al., 2007) , colon (Barker et al., 2007) , and stomach (Barker et al., 2010) can be identified by the specific expression of Lgr5, a G protein-coupled receptor of unknown function. Lgr5 + ISCs are long lived, proliferate continuously, and generate all cell types present in the gut. The onset of intestinal tumorigenesis is driven in most cases by activating mutations in the Wnt signaling pathway. Mouse Lgr5 + cells
give rise to intestinal tumors with higher efficiency than other intestinal epithelial cell populations upon mutational activation of the Wnt pathway (Barker et al., 2008) . This observation suggests that ISCs represent the cell of origin for colorectal cancer (CRC). CRC is the second cause of death by cancer. The current therapeutic strategy for most CRC patients includes surgical resection of the tumor and chemotherapeutic treatment. After curative therapy, a large proportion of CRC patients remain clinically free of disease for months or years. Yet, after such period of remission, cancer recurs in 30%-50% of all cases, generally in the form of metastasis. The risk of cancer recurrence is linked to the stage of the disease at the time of diagnosis (American Joint Cancer Committee [AJCC] staging system). Most Stage I CRC patients (95%-98%) will not develop recurrent cancer, whereas 20%-25% of Stage II and 40%-50% of Stage III CRC patients will experience disease relapse upon treatment. Although a large proportion of deaths by CRC are caused by recurrent tumors, the biological basis for disease relapse remains unknown. Cancer relapse is caused by isolated tumor cells that disseminated prior to resection of the primary tumor and that resisted chemotherapeutic treatments. In some patients, resilient cancer cells eventually resume growth and regenerate a new tumor mass.
Recent studies have evidenced that not all cell populations present in primary CRCs are capable of regenerating a tumor as isolated entities. CRCs contain subsets of cells that can effectively propagate the disease when implanted in an immunodeficient host. These cells, termed tumor-initiating cells, can be identified by the expression of surface markers such as cd133 (O'Brien et al., 2007; Ricci-Vitiani et al., 2007) or cd44 (Dalerba et al., 2007) . Cd133 + or cd44 + cell populations represent a particular subset of aggressive CRC cells. In addition, some indirect evidences suggest a connection between tumor-initiating cells and ISCs. In particular, cd133 and cd44 are expressed in the proliferative compartment of normal crypts (progenitors and ISCs) Zeilstra et al., 2008) . Also, purified cd133 + tumor-initiating cells can be expanded in vitro as an undifferentiated population that upon xenotransplantation generates tumors that contain differentiated-like cells (Vermeulen et al., 2008) . Despite these suggestive observations, a relationship between ISCs and cd133 + /cd44 + tumor cells remains speculative. Also, there is lack of evidence supporting a role of tumor-initiating cells in cancer recurrence.
Genes transcriptionally regulated by the Wnt pathway in the intestinal epithelium are expressed with patterns ranging from restricted expression to ISCs (e.g., Lgr5) to broad expression in proliferative cells (e.g., Myc) ( Van der Flier et al., 2007) . One of such Wnt target genes, the receptor tyrosine kinase EphB2, is expressed in a decreasing gradient from the crypt base toward the differentiated cell compartment (Batlle et al., 2002) . EphB activity is required to establish the position of the different cell types in the crypts as mice mutant for EphB2, EphB3 (Batlle et al., 2002) , or their ligand ephrin-B1 (Cortina et al., 2007) display defects in intestinal cell compartmentalization. Here, we take advantage of EphB2 graded expression to purify and obtain the expression profiles of ISCs and other crypt cell types. We discover that expression of ISC-specific genes associates with Figure S1 and Table S1. the risk of developing recurrent CRC. Furthermore, paralleling the results in normal crypts, the graded expression of EphB2 in CRCs identifies tumor cell populations displaying ISC-like or differentiated-like phenotypes.
RESULTS

Purification and Expression Profiling of ISCs and Other Crypt Cell Types
The transcriptional profiles of the different cell types present in the intestinal epithelium remain essentially uncharacterized, which precludes an in-depth analysis of intestinal cell typespecific gene program expression in CRC. We developed a cell isolation method based on surface expression of EphB2, which is expressed following a decreasing gradient from the crypt base ( Figure 1A ). ISCs (i.e., crypt base columnar cells) showed highest expression of membrane EphB2 ( Figure 1A , black arrowheads), whereas TA cells progressively decreased EphB2 protein levels as they migrated toward the surface. Differentiated cells in the villus and Paneth cells were negative for EphB2 expression (Batlle et al., 2002) . We stained suspensions of disaggregated mouse intestinal cells with a monoclonal antibody directed against the extracellular domain of EphB2 (Mao et al., 2004) , and by FACS, we isolated epithelial cells (EpCAM + , Figure 1B) . Analysis of marker genes revealed similar levels of Ki67, Myc, FoxM1, ( Figure 1C ) and other genes characteristic of proliferating cells in EphB2 hi and EphB2 med cell subpopulations ( Figure S1 available online). However, EphB2 hi cells expressed around 5-fold higher levels of ISC-specific genes Lgr5 (Barker et al., 2007) , Ascl2 (van der Flier et al., 2009), and Olfm4 (van der Flier et al., 2009 ) ( Figure 1C ). These results suggest that the EphB2 hi cell population is enriched in ISCs, whereas EphB2 med cells correspond mainly to crypt TA cells.
To test the functionality of each crypt cell population, freshly isolated cells from mouse small intestine were cultured in conditions that mimic the intestinal stem cell niche as previously described (Sato et al., 2009 ). Single cells expressing high or medium levels of EphB2 developed into complex multicellular 3D structures ( Figure 1D ). These in vitro organoids recreated the organization of the intestinal epithelium, including the presence of multiple crypt-like structures ( Figures 1D and 1F , arrowheads) distributed around a central lumen. EphB2 hi cells showed 3-to 5-fold higher efficiency than EphB2 med cells in the formation of intestinal organoids ( Figure 1E ). This result parallels the enrichment in ISC marker gene expression between EphB2 hi and EphB2 med populations shown in Figure 1C . On the contrary, EphB2 lo and EphB2 neg cells never grew ( Figure 1E ). Organoids derived from single EphB2 hi cells displayed proliferative Ki67 + cells within crypt-like evaginations ( Figure 1G , empty arrowheads) and cell-cycle-arrested Krt20 + differentiated cells forming large lumens ( Figure 1H , arrows). Importantly, staining for lineage-specific markers revealed the presence of all mature intestinal cell types ( Figures 1I-1K ). Organoids were expanded by mechanical disaggregation every 4 to 5 days over a 2 month period without decrease in growth rates. The efficiency of organoid generation from isolated EphB2 hi cells was in the range of 0.5%-1%, similar to that obtained from Lgr5-GFP hi cells in our laboratory (1%-2%; data not shown) and slightly lower than reported before (Sato et al., 2009 (Table S1 ), including the previously described ISC-specific genes Lgr5 (Barker et al., 2007) and Ascl2 (van der Flier et al., 2009 ). The expression of several randomly selected genes from this list (Smoc2, Pcdh8, and Igfbp4) was restricted to small, wedge-like cells intermingled with Paneth cells at the crypt-bottom most positions ( Figure 1L ; data not shown). This pattern is characteristic of Lgr5 + cells (Barker et al., 2007) , implying that these three genes represent new ISC-specific markers. To broaden this analysis, we analyzed the expression of the EphB2 hi ISC signature in Lgr5-GFP knockin mice (Barker et al., 2007) . The vast majority (98%) of genes contained in the EphB2 hi ISC gene expression signature were upregulated (>1.5-fold, p < 0.05) in Lgr5-GFP hi cells relative to Lgr5-GFP lo cells ( Figures S2A-S2C ) (Barker et al., 2007) . Of note, the EphB2 hi ISC gene signature did not contain core pluripotency genes (i.e., oct4, sox2, nanog, klf4) or the Myc-driven gene module characteristic of ESCs (Kim et al., 2010) . It was not enriched in genes directly involved in proliferation owing to equal levels in ISCs and TA cells (see below).
We also established the gene program that defines the proliferation status of crypt cells by selecting probes expressed at equivalent levels in EphB2 hi and EphB2 med cells that were silenced in EphB2 lo cells (Table S1 ). This gene module was enriched in known mediators of DNA replication, mitosis, DNAdamage repair, and proliferation ( Figure 1C and Figure S1 ). Genes with higher expression levels in EphB2 lo compared to EphB2 med cells that were further downregulated in EphB2 hi subpopulation constituted the gene expression signature of late progenitor cells (Table S1 ). This set contained several wellestablished markers of intestinal differentiation such as Krt20, Anpep, or Ada ( Figure 1C , Figure S1 and Table S1 ).
Aggressive CRCs Are Enriched in ISC Gene Expression Each gene expression signature described above was instrumental to investigate whether the global transcriptional profile of human CRCs resembled that of any particular crypt cell type. Crypt proliferation genes were overexpressed in all CRCs compared with normal tissue (Figure 2A ). Remarkably, 38% of the genes from the EphB2 hi ISC gene program were also overexpressed in CRCs, including the bona fide ISC markers Lgr5 and Ascl2 ( Figure 2B ) (average fold change > 1.5, p < 0.05). The signature of late TA cells was silenced overall (Figure 2A ), and Krt20 and other markers of intestinal differentiation were downregulated relative to normal tissue ( Figure 2B and data not shown). We next investigated the association of each crypt cell geneexpression signature with clinical progression of CRC. We selected for analysis a representative pooled cohort of 340 primary colon cancer patients treated at three different hospitals See also Figure S2 and Tables S2, S3 , and S4.
(see Experimental Procedures for details). Gene Set Enrichment Analysis (GSEA) revealed that the expression of EphB2-ISC genes was strongly associated with metastatic compared with nonmetastatic colon cancer ( Figure 2C ; Stage IV versus the rest, FDR < 0.0003; data not shown). In addition, the EphB2-ISC and Proliferation signatures were enriched in poorly differentiated tumors compared to more benign well-differentiated CRCs ( Figure 2D ). To strengthen the above observations, we derived an independent ISC expression signature from Lgr5-GFP cells. We selected those probes more acutely upregulated in Lgr5-GFP hi versus Lgr5-GFP lo cells (>3 fold, p < 0.05, Table S1 ). 54% of the genes contained in the Lgr5-GFP hi signature were not represented in the EphB2 hi ISC signature ( Figure S2D ) due to the different cut-offs used to define both gene lists. Like for EphB2 hi genes, the Lgr5-GFP hi signature was highly enriched in metastatic colon cancer ( Figure S2E ; Stage IV versus the rest; FDR < 1 3 10 À8 ; data not shown) as well as in poorly differentiated compared with well-differentiated tumors ( Figure S2E ). Altogether, these results suggest that a distinctive feature of aggressive colon cancers is high expression of an ISC-like gene program.
Expression of ISC-Specific Genes Predicts Disease Relapse in CRC Patients
GSEA also revealed that the EphB2-derived ISC signature was highly enriched in genes that positively predicted the relative risk of developing recurrent cancer upon intended curative therapy (FDR < 1 3 10 À8 ; Figure 3A ). We used ISC gene expression levels to stratify CRC patients into three groups ( Figure 3B ). Patients bearing primary CRCs with high average expression of ISC genes had a relative risk of relapse 10-fold higher than those with low levels (p < 0.0001). The EphB2-ISC medium expression group displayed an intermediate risk (medium versus low; HR = 6.28; p = 0.0182). Remarkably, the EphB2-ISC low group remained virtually disease-free during 10 years of follow-up with only one early recurrent cancer ( Figure 3B ). The EphB2-ISC signature expression displayed an incremental and approximately linear effect on the risk of recurrence ( Figure 3C ; linearity test, p = 0.5). Multivariate analysis using the Cox Proportional Hazards Model demonstrated that the EphB2-ISC signature is a predictor of disease relapse independent of AJCC staging ( Figure 3D ). We obtained equivalent results for the Lgr5-ISC signature ( Figure S2H ). We noticed that the EphB2-and Lgr5-derived ISC signatures predicted relapse with borderline significance in the multivariate analysis (p = 0.04 and p = 0.02, respectively; Figure 3D and Figure S2H ). Yet, both ISC signatures performed better to identify CRC relapse occurring later than 2 years after curative therapy ( Figure 3B and Figure S2F , dashed lines). GSEA confirmed that both ISC signatures were enriched in genes associated with late (>2 years) compared with early colon cancer relapses ( Figure 3E and Figure S2I ). Remarkably, multivariate analysis revealed that EphB2-ISC ( Figure 3F ) and Lgr5-ISC ( Figure S2J ) signatures outperformed the AJCC staging system in the identification of relapses occurring after 2 years of treatment. Thus, late recurrent tumors appear to arise preferentially from CRCs that expressed high levels of ISC genes.
The gene expression signature obtained from late TA cells was enriched in genes that predicted no relapse over follow-up, albeit with borderline statistical significance (FDR = 0.03; Figure 3A ). In addition, several well-established markers of intestinal differentiation associated inversely with tumor recurrence, including MUC2 (p = 0.024; HR = À1.37), TFF3 (p = 0.011; HR = À1.38), MATH1 (p = 0.0001; HR = À1.54), CDX2 (p = 0.0005; HR = À1.54), or Villin (p = 0.02; HR = À1.31). GSEA also demonstrated that the crypt proliferation signature was inversely associated with disease relapse ( Figure 3A ) as previously reported (Anjomshoaa et al., 2008) . This observation reinforces the notion that ISC and proliferation genes measure independent features of the tumor.
Humanized Colon Crypt ISC Signatures Identify Recurrent CRCs
The gene-expression signatures used in this study were obtained from mouse intestinal cells. We reason that genes involved in essential functions for crypt cells must be largely conserved between human and rodents. Yet, to rule out the possibility that the use of mouse-derived gene lists may impose artifacts in the clinical association studies, we analyzed their overall expression patterns in human colon mucosa. We interrogated a publicly available data set of transcriptomic profiles of normal human colon mucosa in which the top crypt and bottom compartments were microdissected and analyzed separately (Kosinski et al., 2007) . GSEA showed that EphB2-ISC, Lgr5-ISC, and Proliferation signatures were largely enriched in crypt human bottom compared to top region compartments, whereas the Late TA signature followed the reverse pattern ( Figure 4B) . Thus, to a large extent, mouse-derived signatures used in this study are expressed by human colon crypts with equivalent patterns. Using the expression profiles of human colon crypts as filters, we excluded from each mouse crypt-derived cell signature those genes that were not differentially expressed between human colon crypt-bottom and crypt-top compartments (see Experimental Procedures). The resulting ''humanized'' gene lists (Table S5 ) associated with disease progression with equivalent strength and specificity than the unrefined mouse crypt-derived gene lists ( Figures 4C-4F and Figure S3 ). In particular, Hu-EphB2-ISC and Hu-Lgr5-ISC signatures were enriched in metastatic CRC (Stage IV versus the rest, HuEphB2-ISC; FDR = 0.04 and Hu-Lgr5-ISC; FDR < 10
À16
, data not shown) as well as in recurrent tumors (Figure 4C and Figure S3A) . Analogous to the signature of mouse crypt proliferative cells, the Hu-Proliferation signature was enriched in nonrecurrent CRCs (FDR < 10 À16 , data not shown). In addition, GSEA confirmed a further enrichment of Hu-ISC signatures in tumors that will relapse relatively late (>2 years) ( Figure 4D and Figure S3D ). Both Hu-EphB2-ISC and Hu-Lgr5-ISC signatures had approximately linear effect on the risk of recurrence ( Figure 4E and Figure S3B ). Multivariate analysis using the Cox Proportional Hazards Model demonstrates that the power of the humanized ISC signatures to predict relapse is, to a large extent, independent of AJCC staging ( Figure 4F and Figure S3C and S3E). Overall, these results strengthen the specificity of the association of the ISC expression program with the clinical progression of CRC. 
Colorectal Cancers Contain Cells with Either Intestinal Stem Cell-like or Differentiated-like Phenotypes
The above observations indicate that most aggressive CRCs express high levels of ISC-specific genes. This phenomenon is associated to the ability of tumor cells to recur after therapy. We next sought to understand whether the ISC program was homogenously expressed by all tumor cells or restricted to specific subpopulations. We used Lgr5 as a surrogate marker to identify the localization of tumor cells with ISC-like phenotype. By in situ hybridization, we detected Lgr5 mRNA at the base of human colonic crypts ( Figure 5B ) as well as in a large proportion of tumor samples from CRC patients ( Figure 5F ). Lgr5 expression was heterogeneous among different tumors. The frequency of positive cells ranged from <1% to 95% ( Figure 5F ), and staining (C) log-Hazard Ratio (HR) of recurrence as a smooth function of the average ISC expression (penalized quartic splines). Dashed lines, 95% confidence intervals. The effect of average EphB2-ISC score on the recurrence log-hazard ratio did not deviate significantly from linearity (linearity test; p = 0.5).
(D) Multivariate analysis using Cox Proportional Hazards Model to assess dependency of different tumor variables in the prediction of cancer relapse. ISC expression modeled as a linear effect, as supported by (C). We report HR and standardized HR for +1 SD increase in ISC expression.
(E) GSEA of EphB2-ISC signature in late-recurrent (>2 years) versus early-recurrent (%2 years) CRC patients. For this analysis, only recurrent tumors were taken into consideration.
(F) Multivariate analysis of EphB2-ISC signature for late CRC relapse (>2 years). In this analysis, patients that did not relapse over follow-up were compared to those relapsing >2 years after intended curative therapy. See also Figure S2 and Tables S2, S3 and S4. was restricted to cell clusters dispersed throughout the tumor mass (red arrowheads in Figure 5D and Figure S4 ). Commonly, Lgr5 + cells localized within the most basal tumor cell layers. In tumor regions that displayed glandular organization, Lgr5 + cells resided at sites where the tumor epithelium invaginates into the surrounding stroma (dotted lines in Figure 5D and Figure S4) . Remarkably, the morphology of these invaginations was reminiscent of that of normal colon crypts. As exemplified in Figure 5D , some CRCs were constituted by abundant cryptlike structures arrayed around large lumens. Other CRCs contained individual Lgr5 + crypts dispersed throughout the tumor mass (examples in Figure S4 ). Of note, we could not detect the expression of Lgr5 in one-third of the samples analyzed (Figure 5F ) owing to low sensitivity of ISH technique on archival material. This subset included most poorly differentiated CRCs that consistently showed low levels of Lgr5 (data not shown) even though they were, overall, enriched in expression of ISCspecific genes ( Figure 2D and Figure S2E) .
We also investigated the expression of intestinal differentiation markers in CRC. Krt20 codifies for a cytokeratine whose levels increase sharply in late progenitor and differentiated cells of normal crypts ( Figure 5C , black arrowheads). Interestingly, we observed that the expression patterns of Krt20 and Lgr5 in CRC were mutually exclusive. Staining of serial tumor sections demonstrated that Lgr5 + cells were devoid of Krt20 staining, whereas neighboring Krt20 + cells lacked Lgr5 expression (black arrowheads in Figure 5E and Figure S4 ). This complementary expression pattern was found in all Lgr5 + tumors analyzed.
In tumors with glandular growth patterns, Lgr5 mRNA was detected at the base of crypt-like units, whereas Krt20 + cells resided near luminal spaces (insets in Figures 5D and 5E ). Some samples also contained double-negative cells positioned between Lgr5
+ and Krt20 + cells (white arrowheads in Figure 5H and Figure S4B Figure 5H , black arrowheads). From the limited number of marker genes analyzed, we tentatively concluded that a large proportion of CRCs contain cells with two mutually exclusive phenotypes: an ISC-like or a differentiated cell-like phenotype ( Figure 5G ).
EphB2 Is a Surface Marker for ISC-like Tumor Cells
We then investigated whether EphB2 expression could distinguish between ISC-like and differentiated-like cells in CRCs as it does in the normal intestinal mucosa. Figures 6A-6C and Figure S5 show the expression patterns of EphB2, Lgr5, and Krt20 in serial sections of representative CRCs. Most CRCs were composed of cell clusters expressing heterogeneous EphB2 levels ranging from highly positive, to intermediate, to completely negative ( Figure 6A , red, blue, and green arrowheads, respectively). In the vast majority of tumors analyzed (n = 30), prominent EphB2 staining coincided with Lgr5 expression (Figures 6A and 6B, red arrowheads, and Figure S5 ). In glandular tumors, EphB2 and Lgr5 labeled the base of crypt-like structures that grew embedded into the tumor stroma ( Figure 6A and 6B, dashed lines). On the contrary, the majority of Krt20 + tumor cells were EphB2 lo or EphB2 neg in all tumors ( Figures 6A and 6C , green arrowheads, and Figure S5 ). Of note, EphB2 was silenced in areas of high grade as we previously reported (Batlle et al., 2005) . Commonly, these areas also showed low levels of Lgr5 expression (data not shown).
We also analyzed the possibility that markers of tumor initiating cells (TICs) (i.e., cd44 and cd133) recognize ISC-like cells in CRCs. Cd44 and Lgr5 expression domains overlapped largely in most tumors (7 out 9 samples analyzed) ( Figures S6A   and S6B ), yet Krt20 + cells were also partially included in the cd44 + domain in two-thirds of the samples ( Figure S6 ). Cd133
antibody stained the apical membrane of luminal tumor cells whereas, in most cases, ISC-like cells were located in basal positions ( Figures S6G and S6H ). This localization is consistent with that described previously (Shmelkov et al., 2008) . However, it is important to mention that cd133 antibodies used for FACS recognize a conformational epitope in TICs (Kemper et al., 2010) . To strengthen the link between the EphB2 hi tumor cell population and the ISC-like phenotype, we analyzed EphB2 surface expression by flow cytometry on primary CRC biopsies (Figure 6D) . In most tumors, epithelial cells (EpCAM + ) were heterogeneous regarding EphB2 surface abundance with relative levels ranging from 1 to 10 4 ( Figure 6D ). This distribution resem- Figure 6D ). On the contrary, EphB2 lo / EphB2 neg cells were characterized by increased expression of Krt20 as well as of Krt17, another marker of mature colonic cells ( Figure 6D ). Combined immunophenotyping with EphB2 and cd44 antibodies showed that cd44 hi cell populations were enriched in EphB2 hi cells in all samples ( Figure S7A ). Still, EphB2 surface expression distinguished between ISC-like and differentiated-like cells within the cd44 hi population ( Figure S7B ). These results are in agreement with the staining patterns observed in tissue sections and suggest that cd44 marks ISC-like cells albeit with lower specificity than EphB2.
ISC-like Cells Are Tumor-Initiating Cells and Display Self-Renewal and Differentiation Capacity
We then sought to determine the tumorigenic potential of ISClike or differentiated-like tumor cells. As a proof of principle, we purified epithelial tumor cells (EpCAM + ) expressing high, medium, or low surface EphB2 levels ( Figure 7A ) from a stage IV CRC. The relative expression of ISC marker genes Lgr5, Ascl2, Olfm4, and Smoc2 declined from EphB2 hi to EphB2 lo populations ( Figure 7B ). Conversely, expression of pan-intestinal differentiation markers Krt20, Krt17 and Ceacam5 was highest in EphB2 lo cells and decreased progressively in EphB2 med and EphB2 hi cells. Importantly, the three EphB2 populations expressed equal levels of proliferation markers such as Ki67 ( Figure 7B ) and Myc (data not shown).
To test the tumor forming capacity of each EphB2-purified cell population we performed subcutaneous injections into NOD/ Scid mice. The three tumor cell populations (EphB2 hi , EphB2 med , and EphB2 lo ) showed equivalent viability after FACS measured by propidium iodide and trypan blue exclusion (data not shown). Figure 7C shows tumor-free survival plots for mouse cohorts inoculated with different cell dosages. Mice that did not develop tumors were followed over a period of at least 5 months. Figure 7F ). Therefore, the enrichment in tumor initiating cells paralleled the expression of ISC genes. EphB2 hi cells generated xenografts with histological patterns that largely resembled the primary tumor including the presence of EphB2 hi , EphB2 med , and EphB2 lo cells (representative example is shown in Figures 7D and 7E) . Assessment of EphB2 surface abundance by flow cytometry confirmed that engrafted EphB2 hi tumor cells gave rise to EphB2 med and EphB2 lo populations ( Figure 7D ). Remarkably, the relative expression levels of ISC, proliferation, and differentiation marker genes in the three secondary EphB2 populations were analogous to those of the primary xenograft ( Figure 7E) . Thus, few inoculated EphB2 hi cells effectively propagated the disease in immunodeficient hosts while restoring the patterns of ISC-like and differentiated-like cells of the tumor of origin. To strengthen this conclusion, we tested the tumorigenic potential of different populations of secondary and tertiary EphB2 hi -derived xenografts ( Figure 7F ). The frequency of tumor-initiating cells in each secondary and tertiary cell population did not differ significantly from that calculated in the tumor of origin (p > 0.05 for all comparisons) ( Figure 7F ). We conclude that ISC-like tumor cells hold high tumor-initiating potential as well as display long-term self-renewal and differentiation capacity.
DISCUSSION
The association of stem cell genes with disease outcome in several cancer types is widely accepted. This notion has spread from studies that used expression signatures derived from tumor-initiating cells (Glinsky et al., 2005) . These signatures may reflect the gene program of a particularly aggressive population rather than that expressed by adult stem cells. On the other hand, pluripotency genes expressed by embryonic stem cells (ESCs) have also been generally correlated with poor prognosis in cancer (Ben-Porath et al., 2008 ). Yet, the correlation of ESC genes with cancer progression has been recently undermined by the finding that a Myc-driven gene program rather than core pluripotency genes accounts for similarities between ESCs and cancer stem cells (Kim et al., 2010) . Our work provides unequivocal evidence that the risk of developing recurrent CRC is proportional to the expression in the primary tumor of a set of genes specific of normal ISCs. This finding raises the possibility that tumor cells require ISC-specific functions to effectively regenerate cancer after therapy. The robust association of the ISC signature with cases of late relapse favors the idea that ISC genes endow long-term survival and regeneration potential rather than immediate tissue colonization capacity. A recent work by Di Fiore and colleagues correlates higher grading in breast cancers with higher frequencies of cancer cells expressing a breast stem cell-like phenotype (Pece et al., 2010) . Our assessment of ISC gene expression levels may estimate both the relative number of ISC-like cells within a given tumor as well as the overexpression of particular ISC genes co-opted by CRC cells.
The signature of crypt proliferation shows a strong but reverse correlation with CRC recurrence. A similar association was reported independently (Anjomshoaa et al., 2008) , and it is in sharp contrast to the results obtained for breast cancer where a high proliferative index indicates poor prognosis (Anjomshoaa et al., 2008) . It remains to be determined whether high levels of proliferation genes in CRC modify the efficacy of chemotherapeutic drugs that target the cell division machinery. In any case, a straight interpretation of this result is that the predictive power of ISC genes for relapse does not stem from their role in 
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Intestinal Stem-like Cells in Colorectal Cancer Relapse proliferation. On the other hand, we found that expression of several individual markers of intestinal differentiation in the primary tumor associates with good prognosis. The late TA signature is also enriched in genes that inversely predicted disease relapse yet with borderline significance. We speculate that this may be due to incomplete or aberrant expression of the differentiation program by CRC cells. In tumor tissue, ISC and differentiation programs are expressed with mutually exclusive patterns that resemble those of the normal intestinal mucosa. We identify a subpopulation of tumor cells with an ISC-like phenotype that localizes in close proximity to cells that express intestinal differentiation genes. In well-and moderately differentiated CRCs, these two cell types reside within defined structures reminiscent of intestinal crypts. In healthy intestinal mucosa, high EphB2 levels mark cells at the crypt base (i.e., ISCs), whereas the ISC progeny gradually silences EphB2 expression as it migrates away from the stem cell niche. The EphB2 expression gradient is required to compartmentalize cell populations in different territories of the healthy epithelium (Batlle et al., 2002) . FACS analysis demonstrates that CRCs display a graded expression of EphB2 reminiscent of that of intestinal crypts. ISC-like tumor cells are EphB2 hi and reside closer to the stroma whereas differentiated-like cells are low or negative for EphB2 expression and face the luminal sides of tumor glands. Thus, like in normal epithelium, the identity and position of ISC-like and differentiated-like cells within the tumor correlates with different EphB2 surface levels. This pattern is common to a large proportion of CRCs except for poorly differentiated tumors that express low EphB2 levels as we previously reported (Batlle et al., 2005) . Mouse colon tumors engineered to lack EphB signaling acquire a nonglandular growth pattern characterized by loss of cell polarity and an aggressive phenotype (Batlle et al., 2005; Cortina et al., 2007) . Thus, EphB2 silencing in ISC-like cells may contribute to the loose architecture of poorly differentiated CRCs. Besides the downregulation of EphB2, GSEA demonstrates that poorly differentiated CRCs retain an overall ISClike phenotype compared with well-differentiated tumors. It would be beneficial to identify additional ISC marker genes that label the EphB2 neg tumor stem cell population in poorly differentiated CRCs.
A central question that arises from our observations is how the ISC and differentiated programs are maintained in CRC. A recent report demonstrates that tumor cells grown in vitro as colonospheres display different amounts of b-catenin/Tcf signaling that, in turn, regulate the expression of stem cell or differentiation markers . Also, in some CRCs, strongest nuclear b-catenin accumulation corresponds to tumor cells positioned closer to the tumor stroma (Brabletz et al., 2001 ). This localization is consistent with the Lgr5 expression domain reported here. Thus, differential Wnt signaling may account for the establishment of ISC-like or differentiated-like populations in a subset of CRCs. Other pathways involved in the balancing of the differentiation and stem cell programs in normal crypts such as Notch or BMP signaling may potentially regulate the relative numbers of ISC-and differentiated-like cells in tumors.
We have shown that primary tumors and metastasis share an equivalent distribution of ISC-like and differentiated-like cell populations. Apparently, the disseminated cell that propagates the disease to the metastasic site reconstitutes the populations and organization of the tumor of origin. ISC-like tumor cells are candidates to represent tumor propagating cells in CRC as they generate tumors in immunodeficient hosts with high efficiency compared with differentiated-like cells. In addition, tumors generated from ISC-like cells recapitulate the organization of the tumor of origin. These two features parallel the selfrenewal and differentiation properties of normal ISCs. Our results also indicate that the previously identified cd44 + tumor-initiating cell population is partially enriched in ISC-like cells. Overall, these discoveries strengthen the view of a hierarchical organization of CRC cells similar to that present in normal crypts and suggest that ISC-like cells are the tumor cell population that instigates recurrent cancers.
EXPERIMENTAL PROCEDURES
Histological Procedures
Detailed protocols for Immunohistochemistry, in situ hybridization, and immunofluorescence are provided in Supplemental Information.
Intestinal Crypt Cell Purification and In Vitro Growth
A detailed protocol for the purification of crypt cell types according to EphB2 expression is available in the Supplemental Information section. In vitro growth of intestinal organoids and FACS purification of Lgr5-GFP hi or Lgr5-GFP lo cells were performed as previously described (Sato et al., 2009 ).
Generation of Crypt Cell Gene-Expression Signatures
We measured gene-expression levels of three EphB2 selected populations in two independent experiments using Affymetrix mouse4302 arrays. For a detailed description of the statistical method to define each crypt expression signature, please refer to Supplemental Information.
CRC Patient Gene Expression Data Sets and Association of Crypt Expression Signatures with Clinical Outcome
At the moment of performing this study, there were six publicly available CRC gene expression datasets annotated with clinical information in the Gene Expression Omnibus at NCBI (GSE17538, GSE10402, GSE12945, GSE5206, GSE12032 and GSE14333). We compared the robustness and accuracy of these data sets (see Supplementary Information) and selected datasets GSE17538 (Smith et al., 2010) and GSE14333 (Jorissen et al., 2009 ) for further analysis. We combined both cohorts for a total of 340 unique CRC expression profiles. For descriptive statistics as well as association of major clinical progression parameters and clinical outcome for this cohort, please refer to Supplemental Experimental Procedures and Tables S3 and S4 . Detailed descriptions of all statistical analysis employed in this manuscript are included in Supplemental Information.
Analysis of Mouse Signatures in Human Colon Crypt Top and Bottom Compartments
We used the GSE6894 dataset (Kosinski et al., 2007) , which contains expression profiles of microdissected human colon crypt top and bottom compartments (n = 9 pairs from different mucosa samples). We refined the ISC, Lgr5, and proliferation signatures by selecting genes differentially expressed in human colon crypts (crypt-bottom > crypt-top for EphB2-ISC, Lgr5-ISC, and proliferation signatures and crypt-top > crypt-bottom for Late TA genes, >1.5-fold in all cases).
Tumor Disaggregation and Sorting of EphB2 Cell Populations and Assays of Tumor Initiation
Primary tumor samples were obtained from Hospital del Mar (Barcelona, Spain) or Hospital de la Santa Creu i Sant Pau (Barcelona, Spain). Detailed protocols for tumor dissagregation and tumor cell purification are described under Supplemental Experimental Procedures. Different EphB2-purified cell fractions were injected s.c. into NOD/Scid mice. Tumor growth was monitored over 5 months. Frequency of tumor-initiating cells was estimated according to published methods (Hu and Smyth, 2009 ).
ACCESSION NUMBERS
Microarray data are accessible at the Gene Expression Omnibus (GEO) database under accession number GSE27605.
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